Zanamivir: A rational approach to influenza B

Scandinavian Journal of Infectious Diseases

Volumn 33, Issue 1, 2001, Pages 33-40

  Penn, C R ^a   Osterhaus, A ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 DEOXY 2,3 DEHYDRO N ACETYL NEURAMINIC ACID; 2 DEOXY 2,3 DEHYDRO N TRIFLUOROACETYL NEURAMINIC ACID; 4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; AMANTADINE; INFLUENZA VACCINE; OSELTAMIVIR; PLACEBO; RIBAVIRIN; RIMANTADINE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR;

ADULT; ANIMAL MODEL; ARTICLE; CHEMOPROPHYLAXIS; CHILD; CIRCULATION; CONTROLLED STUDY; DISEASE CARRIER; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; EPIDEMIC; GENETIC DRIFT; GENETIC RECOMBINATION; HUMAN; HUMAN CELL; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; MOUSE; NONHUMAN; RESPIRATORY SYSTEM; SEROLOGY; SPECIES; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; GUANIDINES; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; NEURAMINIDASE; PYRANS; SIALIC ACIDS; ZANAMIVIR;

EID: 0035133798     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655401750064040     Document Type: Article

References (68)

1. The socioeconomic aspects and behavioural effects of influenza
2. Acute respiratory disease hospitalizations as a measure of impact of epidemic influenza
3. The impact of influenza epidemics on mortality: Introducing a severity index
4. Human influenza
5. Genetic reassortment of human influenza viruses in nature
6. Characterization of the surface proteins of influenza A (H5N1) viruses isolated from humans in 1997-1998
7. A pandemic warning?
8. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus
9. Acute respiratory illness in the community. Frequency of illness and the agents involved
10. Managing influenza in primary care
11. The effectiveness of vaccination against influenza in healthy, working adults
12. Socioeconomics of influenza and influenza vaccination in Europe
13. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
14. Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: A double-blind, multicenter, placebo-controlled trial
15. Role of hemagglutinin cleavage for the pathogenicity genicity of influenza virus
16. Structure and function of the neuraminidase
17. Immunology of influenza
18. Studies on the primary structure of the influenza virus haemagglutinin
19. The molecular epidemiology of influenza viruses
20. Ion channel activity of influenza A virus M2 protein: Characterization of the amantadine block
21. Amantadine and rimantadine
22. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2.3-dehydro-N-trifluoroacetyl-neuraminic acid (FANA): Mechanism of action
23. 2-Deoxy-2.3-dehydrosialic acids. II. Competitive inhibition of Vibrio cholerae neuraminidase by 2-deoxy-2,3-dehydro-N-acylneuraminic acids
24. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution
25. Structure of the catalytic and antigenic sites in influenza virus neuraminidase
26. Rational design of potent sialidase-based inhibitors of influenza virus replication
27. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza
28. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: Randomized controlled trials for prevention and treatment
29. Efficacy of oral oseltamivir in experimental human influenza B virus infection (Abstract 1670).; 37th Annual Meeting
30. 2.3-Didehydro-2,4-dideoxy-4-guanidino-N-acetyl-d-neuraminic acid (4-guanidino-Neu5Ac2en) is a slow-binding inhibitor of sialidase from both influenza A virus and influenza B virus
31. Three-dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase
32. Dihydropyrancarboxamides related to zanamivir: A new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological 4-amino-4H-pyran-6-carboxamides
33. Dihydropyrancarboxamides related to zanamivir: A new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from virus types A and B
34. Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors
35. GS4071 is a slow-binding inhibitor of influenza neuraminidase from both A and B strains
36. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro
37. Inhibition of the growth of influenza viruses in vitro by 4-guanidino-2,4-dideoxy-N-acetylneuraminic acid
38. Inhibition of replication of avian influenza viruses by the neuraminidase inhibitor 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid
39. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase)
40. GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets
41. Characterization of influenza A HongKong/156/97 (H5N1) virus in a mouse model and protective effect of zanamivir on H5N1 infection in mice
42. Mutation in the influenza virus neuraminidase gene resulting in decreased sensitivity to the neuraminidase inhibitor 4-guanidino-Neu5Ac2en leads to instability of the enzyme
43. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en
44. Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en
45. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en
46. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en
47. Selection of influenza virus with reduced sensitivity in vitro to the neuraminidase inhibitor GG167 (4-guanidino-Neu5Ac2en): Changes in the haemagglutinin may compensate for loss of neuraminidase activity
48. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers
49. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers
50. Evidence for zanamivir resistance in an immuno-compromised child infected with influenza B virus
51. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza
52. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection
53. Effects of the neuraminidase inhibitor zanamavir on otologic manifestations of experimental human influenza
54. GG167 Influenza Study Group. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections
55. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections
56. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections
57. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: A randomized, double-blind, placebo-controlled European study
58. Relenza: Summary of product characteristics
59. The efficacy of inhaled zanamivir in the treatment of influenza B (Abstract 0281)
60. Randomised, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: Pooled efficacy analysis
61. Zanamivir in the prevention of influenza among healthy adults: A randomized controlled trial
62. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks
63. Estimating influenza-related hospitalization in The Netherlands
64. Trends in infectious disease mortality in the United States during the 20th century
65. Control of influenza. Public health policies
66. Clinical effectiveness, policies, and practices for influenza and pneumococcal vaccines
67. In vivo selection of an influenza A2 strain resistant to amantadine
68. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families